The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial
Abstract
AIMS: In patients with persistent atrial fibrillation (AF), the efficacy and safety of two anti-arrhythmic drugs in preventing the recurrence of AF after successful direct current (DC) cardioversion was prospectively assessed in a multi-centre double-blind, placebo-controlled, randomised trial using daily trans-telephonic monitoring. METHODS AND RESULTS: 1182 patients with persistent AF were prospectively enrolled, 848 patients were successfully cardioverted and then randomised to either sotalol (383 patients), quinidine plus verapamil (377 patients) or placebo (88 patients). The primary outcome parameter was AF recurrence or death. All patients received an event recorder (Tele-ECG) and had to record and transmit via telephone at least one ECG per day during follow-up. The mean follow-up period was 266 days. A total of 191,103 Tele-ECGs were recorded and transmitted. The primary outcome parameter (AF recurrence of any kind or death) was observed in 572 patients (67%) in whom at least one episode of AF recurrence was documented during follow-up, in 348 patients (41%) AF recurrence was persistent. The recurrence rates after one year for any AF were 83% for placebo, 67% for sotalol and 65% for quinidine plus verapamil, the latter being statistically superior to placebo but not different from sotalol. The recurrence rates for the secondary outcome parameter persistent AF were 77%, 49% and 38%, respectively. Quinidine plus verapamil was significantly superior to placebo and to sotalol. About 95% of all AF recurrences were initially detected in the daily Tele-ECG, about 70% of all AF recurrences occurred completely asymptomatic. Adverse events on sotalol and quinidine plus verapamil were comparable with the exception that all torsade de pointes tachycardias occurred on sotalol. CONCLUSION: Anti-arrhythmic treatment after DC cardioversion of persistent AF significantly decreases the recurrence rates of persistent AF compared to placebo with superiority of quinidine plus verapamil compared to sotalol. Symptoms were not reliable as clinical surrogates to detect episodes of AF.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Periodic ECG analysis for proarrhythmia signs has been used successfully in recent antiarrhythmic drug trials.118,584,672”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [118]
In the citing paper
“ECG monitoring was used systematically on days 1-3 in patients receiving flecainide, propafenone, or sotalol to identify those at risk of proarrhythmia.118,584,601”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [118]
Citations
Cites
Amiodarone to Prevent Recurrence of Atrial Fibrillation
Roy, D., Talajic, M. R., Dorian, P., Connolly, S. J., Eisenberg, M. J., Green, M. S., Kuś, T., Lambert, J., Dubuc, M., Gagné, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421302 · Cited by 1,142
Coplen, S. E., Antman, E. M., Berlin, J. A., Hewitt, P., & Chalmers, T. C. (1990) · Circulation · doi:10.1161/01.cir.82.4.1106 · Cited by 946
Management of Patients With Atrial Fibrillation
Prystowsky, E. N., Benson, D. W., Fuster, V., Hart, R. G., Kay, G. N., Myerburg, R. J., Naccarelli, G. V., & Wyse, D. G. (1996) · Circulation · doi:10.1161/01.cir.93.6.1262 · Cited by 638
Page, R. L., Wilkinson, W. E., Clair, W. K., McCarthy, E. A., & Pritchett, E. L. (1994) · Circulation · doi:10.1161/01.cir.89.1.224 · Cited by 627
Fuster, V., Rydén, L., ASINGER, R. W., Cannom, D. S., Crijns, H. J. G. M., Frye, R. L., Halperin, J. L., Kay, G. N., Klein, W. W., Lévy, S., et al. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2983 · Cited by 491
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation
Lafuente‐Lafuente, C., Valembois, L., Bergmann, J., & Belmin, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005049.pub4 · Cited by 450
Juul‐Möller, S., Edvardsson, N. G., & Rehnqvist-Ahlberg, N. (1990) · Circulation · doi:10.1161/01.cir.82.6.1932 · Cited by 343
Verapamil Reduces Tachycardia-Induced Electrical Remodeling of the Atria
Tieleman, R. G., de Langen, C. D. J., Gelder, I. C. V., de Kam, P. J., Grandjean, J. G., Bel, K. J., WIJFFELS, M. C. E. F., Allessie, M. A., & Crijns, H. J. G. M. (1997) · Circulation · doi:10.1161/01.cir.95.7.1945 · Cited by 340
Anderson, J. L., Gilbert, E. M., Alpert, B. L., Henthorn, R. W., Waldo, A. L., Bhandari, A. K., Hawkinson, R. W., & Pritchett, E. L. C. (1989) · Circulation · doi:10.1161/01.cir.80.6.1557 · Cited by 287
Classification of atrial fibrillation
Gallagher, M. M., & Camm, J. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00736-x · Cited by 167
Asymptomatic or “Silent” Atrial Fibrillation
Page, R. L., Tilsch, T. W., Connolly, S. J., Schnell, D., Marcello, S. R., Wilkinson, W. E., & Pritchett, E. L. C. (2003) · Circulation · doi:10.1161/01.cir.0000051455.44919.73 · Cited by 165
Shimizu, W., Ohe, T., Kurita, T., Kawade, M., Arakaki, Y., Aihara, N., Kamakura, S., Kamiya, T., & Shimomura, K. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00313-4 · Cited by 164
Maisel, W. H., Kuntz, K. M., Reimold, S. C., Lee, T. H., Antman, E. M., Friedman, P. L., & Stevenson, W. G. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-4-199708150-00004 · Cited by 122
Plewan, A. (2001) · European Heart Journal · doi:10.1053/euhj.2000.2546 · Cited by 111
Akhtar, M., BREITHARDT, G. E., Camm, A. J., Coumel, P., Janse, M. J., Lazzara, R., Myerburg, R. J., Schwartz, P. J., Waldo, A. L., & Wellens, H. J. J. (1990) · Circulation · doi:10.1161/01.cir.81.3.1123 · Cited by 109
Regression models: calculating the confidence interval of effects in the presence of interactions
Figueiras, A., Domenech, J. M., & Cadarso-Suárez, C. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980930)17:18 · Cited by 104
Double-Blind Placebo-Controlled Trial of Digoxin in Symptomatic Paroxysmal Atrial Fibrillation
MURGATROYD, F. D., Gibson, S., Baiyan, X., O'Nunain, S. S., Poloniecki, J. D., Ward, D. E., Malík, M., & Camm, A. J. (1999) · Circulation · doi:10.1161/01.cir.99.21.2765 · Cited by 80
Simone, A. D. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00311-7 · Cited by 75
Wolk, R. A., Kułakowski, P., Karczmarewicz, S., Karpiński, G., Makowska, E., Czepiel, A., & Ceremuzyński, L. (1996) · International Journal of Cardiology · doi:10.1016/0167-5273(96)02631-9 · Cited by 43
Takanaka, C., & Singh, B. N. (1990) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(90)90205-4 · Cited by 42
Role of Early Afterdepolarization in Familial Long QTU Syndrome and Torsade de Pointes
ZHOU, J., Zheng, L., & LIU, W. (1992) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.1992.tb03041.x · Cited by 24
Anticholinergic Overdose Induced Torsade de Pointes Successfully Treated with Verapamil.
Liao, W.-B., Bullard, M. J., Kuo, C.-T., Hsiao, C., Chu, P., & CHIANG, C.-W. (1996) · Japanese Heart Journal · doi:10.1536/ihj.37.925 · Cited by 19
Simone, A. D., Pasquale, M. D., & Matteis, C. D. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.10.019 · Cited by 13
Heilmann, E., Bender, F., Bachour, G., Brisse, B., & Gradaus, D. (1972) · PubMed · Cited by 13
Page, R. L., Tilsch, T. W., & Connolly, S. J. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00209-5 · Cited by 9
Gülker, H., Bender, F., Heuer, H., & Thale, J. (1982) · PubMed · Cited by 7
高仲, 知. (2001) · Medical Entomology and Zoology · Cited by 2
Flagged first, then by citations
Cited by
Sorted by citations
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 10,550
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P. F., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellà, M., Diener, H., Heidbüchel, H., Hendriks, J., et al. (2016) · EP Europace · doi:10.1093/europace/euw295 · Cited by 6,438
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,924
Metadata
- Authors
- FETSCH, T.
- Affiliations
- University Hospital Münster (DE)
- Corresponding author
- FETSCH, T
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08
- Volume
- 25
- Issue
- 16
- Pages
- 1385-1394
- ISSN
- 0195-668X (ISSN-L)
- OpenAlex
- W2126416532
- Cited by
- 334
- References
- 27
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 9 · 2023: 8 · 2022: 2 · 2021: 11 · 2020: 7 · 2019: 7 · 2018: 13 · 2017: 13 · 2016: 15 · 2015: 11 · 2014: 10 · 2013: 14 · 2012: 20
- FWCI
- 17.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- persistent atrial fibrillation, atrial fibrillation recurrence, electrical cardioversion, sotalol, quinidine, verapamil, antiarrhythmic drugs, remote patient monitoring, event data recorders, torsades de pointes
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Anti-Arrhythmia Agents, Atrial Fibrillation, Double-Blind Method, Drug Therapy, Combination, Electric Countershock, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Quinidine, Sotalol, Verapamil, Survival Analysis, Treatment Outcome, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
